PFG Investments LLC Decreases Stake in Moderna, Inc. (NASDAQ:MRNA)

PFG Investments LLC decreased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 7.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 3,193 shares of the company’s stock after selling 252 shares during the period. PFG Investments LLC’s holdings in Moderna were worth $379,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC purchased a new position in shares of Moderna in the 2nd quarter valued at $26,000. Ogorek Anthony Joseph NY ADV acquired a new stake in Moderna in the 4th quarter valued at $27,000. Cedar Wealth Management LLC raised its position in Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the period. Westside Investment Management Inc. acquired a new position in shares of Moderna during the first quarter worth about $32,000. Finally, Family Firm Inc. acquired a new position in shares of Moderna during the second quarter worth about $33,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the completion of the transaction, the president now directly owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $138.16, for a total value of $2,072,400.00. Following the completion of the sale, the president now directly owns 1,457,089 shares in the company, valued at approximately $201,311,416.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 108,158 shares of company stock valued at $13,239,712. Company insiders own 15.70% of the company’s stock.

Moderna Trading Down 12.4 %

NASDAQ:MRNA opened at $69.68 on Friday. The company has a market cap of $26.78 billion, a PE ratio of -4.45 and a beta of 1.68. The business’s 50 day moving average is $96.06 and its two-hundred day moving average is $111.86. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. The firm had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same period last year, the business posted ($3.62) earnings per share. On average, analysts predict that Moderna, Inc. will post -9.52 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on MRNA. Oppenheimer raised their target price on Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, June 12th. Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Piper Sandler restated an “overweight” rating and issued a $157.00 target price (down from $214.00) on shares of Moderna in a research note on Friday, August 2nd. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and dropped their price target for the stock from $85.00 to $80.00 in a research note on Wednesday, August 7th. Finally, Barclays decreased their price objective on shares of Moderna from $168.00 to $155.00 and set an “overweight” rating for the company in a research report on Friday, August 2nd. Ten research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $123.79.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.